Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics plc (Nasdaq: AUTL) announced the presentation of three innovative cell programming approaches at the American Society of Gene & Cell Therapy (ASGCT) from May 16-19, 2022. Dr. Martin Pule emphasized the importance of enhancing T cell therapy through improved targeting and activity for better patient outcomes. The posters include:
- Enhancing CAR T Cell Therapy Using Cytokine Receptors
- Fas-CD40 Chimera for Better T Cell Effectiveness in Solid Tumors
- Minocycline as a Tuning Control for CAR T Cell Activation
These advancements aim to enhance cancer treatment outcomes.
Autolus Therapeutics plc (Nasdaq: AUTL) has received RMAT designation from the FDA for its lead gene therapy, obe-cel, designed for adult patients with relapsed/refractory B-Acute Lymphocytic Leukemia (ALL). This designation recognizes the therapy's potential to fulfill unmet medical needs and facilitates the drug development process. obe-cel has also received PRIME and ILAP designations in Europe. The ongoing FELIX Phase 2 trial aims to enroll 140 patients across multiple centers. This milestone underscores the importance of obe-cel in addressing critical treatment gaps in adult B-ALL.
Autolus Therapeutics plc (Nasdaq: AUTL) will report its Q1 2022 financial results and operational highlights on May 5, 2022, before U.S. markets open. A conference call and webcast will follow at 8:30 am ET/1:30 pm BST for management to discuss the results and provide a business update. Investors can access the presentation and call via Autolus' website or by dialing provided numbers for U.S. and international listeners. The call will be available for replay for one week.
Autolus Therapeutics (AUTL) has received Orphan Medical Product Designation from the European Medicines Agency for its CAR T therapy, obe-cel, aimed at treating acute lymphoblastic leukemia (ALL). This milestone follows a similar designation from the FDA in 2019. The designation offers benefits such as fee reductions and ten years of market exclusivity post-approval. Ongoing clinical trials for obe-cel focus on its efficacy and safety in adult ALL patients, with first Phase 2 data expected later this year, indicating progress in addressing urgent treatment needs.
Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in three notable investor conferences: the Wells Fargo Annual Biotech Forum on April 12-13, the 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45 am ET, and the 14th Kempen Life Sciences Conference on April 21, with timing to be confirmed. Management will present, and audio webcasts will be available live and archived on the company’s website. Autolus focuses on developing advanced T cell therapies targeting cancer, with a diverse pipeline aimed at treating hematological malignancies and solid tumors.
Autolus Therapeutics plc (Nasdaq: AUTL) reported its financial results for Q4 and full-year 2021 on March 10, 2022. The company secured a $150M collaboration with Blackstone Life Sciences, with potential additional milestone payments of $100M. Notable clinical data from its obe-cel therapy displays a favorable safety profile. Autolus has cash reserves of $310.3M, extending its financial runway into 2024, despite a net loss of $142.1M for the year, a slight improvement over 2020. Key clinical milestones are anticipated in 2022 for therapies targeting various cancers.
Autolus Therapeutics (Nasdaq: AUTL) announced a publication in BioTechniques detailing a novel technology for controlled expression of gene modules, crucial in T cell therapy for cancer treatment. This method allows for very low expression levels of toxic genes, enhancing safety while maintaining efficacy. By utilizing a translational readthrough mechanism, the technology improves CAR T cell therapies targeting solid tumors, specifically allowing controlled IL-12 release without systemic toxicity. This innovation aims to maximize anti-tumor activity while minimizing risks to patients.
Autolus Therapeutics plc (Nasdaq: AUTL) will announce its fourth quarter and full year 2021 financial results and operational highlights on March 10, 2022, before U.S. market open. The management team will host a conference call at 8:30 am ET to discuss the results and provide a business update. Interested parties can access the call via webcast, with a replay available for one week afterward. This event marks a critical opportunity for investors to evaluate the company’s performance in the clinical-stage biopharmaceutical sector focused on T cell therapies.
Engitix has successfully closed a
Autolus Therapeutics plc (Nasdaq: AUTL) announces the retirement of CFO Andrew J. Oakley on March 31, 2022, transitioning to a non-executive director role while remaining an advisor until March 2023. Dr. Lucinda Crabtree, currently SVP of Finance, will succeed him. Oakley highlighted the company's strong financial position following a deal with Blackstone Life Sciences, allowing for strategic advancement of its lead candidate, obe-cel. Crabtree brings extensive financial experience and previously oversaw major public offerings for Autolus.